Journal articleCancer Lett2022
Small molecule inhibitor against onco-mucins disrupts Src/FosL1 axis to enhance gemcitabine efficacy in pancreatic ductal adenocarcinoma.
- Journal
- Cancer Lett
- Published
- 19 September 2022
- Citations
- 13
- Type
- Article
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Grants 11
- Project 1: The Role and Mechanism(s) of MUC16 and MUC16-Cter in Potentiating PC Metastasis P01CA217798↗
- Targeting Mucin and EGFR Axis in Pancreatic Cancer R01CA183459↗
- Targeted Radiation Therapy for Pancreatic Cancer R01CA195586↗
- Rac1 GTPase in tumorigenesis and progression of pancreatic cancer R01CA206444↗
- Role of PD2/Paf1 in Pancreatic Acinar to Ductal Metaplasia R01CA210637↗
- Targeting CXCR2 axis in Pancreatic Cancer R01CA228524↗
- Molecular Imaging Probe(s) for Optical Surgical Navigation of Pancreatic Cancer R01CA256973↗
- Novel Therapy to Inhibit IPMN Progression R01CA263575↗
- Truncated O-glycan-dependent mechanisms inducing metastatic dissemination in pancreatic cancer R01CA273349↗
- Validation of biomarkers for risk prediction and early diagnosis of Pancreatic Adenocarcinoma U01CA200466↗
- Pancreatic Cancer Detection Consortium U01CA210240↗